Abstract: Ocular involvement by plasmablastic lymphoma is extremely rare with very few reports in the literature. Its morphological and immunological resemblance to plasma cell myeloma makes it a diagnostic challenge, while its clinical course, which is characterized by recurrence and death, makes therapy a challenge for clinicians. We present three cases of plasmablastic lymphoma, each of which has distinct clinicoradiological features, and we also review the literature on orbital plasmablastic lymphomas.
Introduction
Ocular adnexal lymphomas are rare, accounting for only 1% to 2% of all lymphomas. 1 The current World Health Organization classification recognizes plasmablastic lymphoma (PBL) as a distinct subtype of diffuse large B-cell lymphoma (DLBCL), characterized by the presence of neoplastic cells resembling B immunoblasts, but that have immunophenotypic features of plasma cells. 2 PBL was first described to involve the oral cavity of predominantly human immunodeficiency virus (HIV)-positive patients. 3 Recently, several reports and case series have published the occurrence of PBL in other anatomical locations and in HIV-negative patients. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Ocular involvement by PBL is extremely rare with very few reports in the literature. [9] [10] [11] [12] [13] [14] [15] Its morphological and immunological resemblance to plasma cell myeloma makes it a diagnostic challenge, while its clinical course, which is characterized by recurrence and death, makes therapy a challenge for clinicians. We present three cases of PBL, each of which has distinct clinicoradiological features, and we also review the literature on orbital PBLs.
skin. Resistance was observed on retropulsion. Computerized tomography of the orbit showed a well-defined, large soft tissue mass, 4.0 cm × 3.0 cm × 2.6 cm in size, confined to the superolateral aspect of the right orbit with significant bony erosion involving the lateral wall with contiguous extension into the temporal fossa ( Figure 1B) .
Microscopic examination showed a diffuse tumor composed of discohesive, large, round lymphoid cells with moderate amounts of amphophilic cytoplasm, eccentric to the central nucleus, and a prominent nucleolus in many of the cells (Figure 2A) . A significant population of tumor cells had a plasmacytoid appearance, and both normal and abnormal mitotic figures were seen. Immunostaining revealed no immunoreactivity for CD20 ( Figure 2B ) and CD45, but a strong, membranous expression of CD138 was noted ( Figure 2C ). The Ki-67 labeling index was 98% ( Figure 2D ). A diagnosis of PBL was confirmed. Serum protein electrophoresis was within normal limits. Chest X-ray and systemic examination were normal. A bone marrow aspiration and trephine biopsy were performed, which was normal. Our patient was staged as Ann Arbor 1A. An HIV screening test was performed and was found to be negative. The patient died within a week following diagnosis, even before further treatment could be initiated.
Case 2
A 45-year-old Indian male was referred to our oncology clinic with protrusion of the left eye, as well as associated redness, watering, and pain. At presentation, his BCVA was 20/25 in the right eye and limited to light perception in the left eye. Conjunctival chemosis was observed with severe proptosis of the left eye ( Figure 3A) . Fundus examination could not be performed. Computed tomography showed a large hypodense mass in the anterior orbit on the superior and superolateral aspects of the globe. The mass indented the globe and was seen causing bony destruction with intracranial extension involving the frontal sinus and the ethmoid sinus ( Figure 3B ). Since the patient had a history of severe weight loss in the past 3 months, an HIV screening test was performed and was found to be positive.
Microscopic examination of the incision biopsy showed a diffuse tumor composed of a monotonous population of plasmacytoid cells with eccentric nuclei and a conspicuous to prominent nucleolus. Mitotic activity was brisk. Immunohistochemically, CD3, CD20, and CD5 were found to be negative. The tumor cells expressed strong membranous immunoreactivity for CD138 and weak reactivity for levocyte common antigen (LCA) (CD45). The Ki-67 index was close to 100%. No light chain restriction was seen. Morphology and immunostaining patterns were confirmative of a PBL.
Bone marrow aspiration done as part of the staging protocol revealed involvement by PBL. Ultrasonography of the abdomen revealed multiple deposits in the liver. Serum lactate dehydrogenase was normal. Our patient was thus staged as Ann Arbor 4.
He was commenced on highly active antiretroviral therapy (HAART) as well as on the cyclophosphamide, hydroxydanorubicin, oncovin, and prednisone (CHOP) regimen. The patient refused chemotherapy and died 6 months following presentation.
Case 3
A 48-year-old Indian male presented with complaints of pain, redness, and watering in the left eye for the previous 3 days. At presentation, his BCVA was limited to finger counting and light perception in the affected eye. Clinical examination revealed proptosis with edema, tenderness and edema of the left upper and lower lids, and complete mechanical ptosis with restricted motility of the globe in all gazes ( Figure 4A ). Conjunctival chemosis was observed, and the rest of the anterior segment details could not be assessed. Severe periorbital, nonpitting edema with severe tenderness and bluish discoloration of the overlying skin accompanied by skin blistering was seen ( Figure 4B ). Upper lip edema with blisters were also noted ( Figure 4B ). A computerized tomography performed at this consultation showed a diffuse mass occupying the entire superior orbit with extension into the temporal fossa and orbital apex with globe compression and stretching of the optic nerve ( Figure 4C and D). An incision biopsy was performed.
Microscopic examination showed a diffuse tumor composed of large plasmablastic cells with eosinophilic to amphophilic cytoplasms and an eccentric vesicular nucleus having prominent nucleoli. Mitotic activity was brisk. Few apoptotic bodies and occasional binucleate cells were also seen. Immunohistochemistry revealed negative staining for CD45 and CD20. Strong membranous positivity for CD138 was observed. The Ki-67 index was 97%-98%. This confirmed the diagnosis of a PBL. An HIV screening test was performed and was found to be positive. Bone marrow aspiration did not reveal involvement by PBL. HAART therapy was commenced. that included adriamycin, vincristine, and cyclophosphamide, the patient is still alive at 3 months postdiagnosis with improvement.
Discussion
PBL is a rare subtype of DLBCL. Ocular involvement by PBL is even rarer. Of all lymphomas diagnosed in our institute, PBL accounted for 0.62%. A large study showed that PBL has a mean age of 39 years at presentation in HIV-positive patients and 54 years in HIV-negative patients. 16 In patients with ocular involvement, including those in this case series; the mean age at presentation in HIV-positive patients was 44.8 years. PBL presents more commonly in men than women. 18 Of all the cases of PBL published in the literature with orbital involvement, 71.4% were males; in our series, 66.6% were males.
9-13 PBL very rarely occurs in children.
19-21 Table 1 summarizes the clinical, radiological, and histopathological features of ocular PBL reported in the literature. PBL accounts for 2.6% of all AIDS-related lymphomas. 15 In a literature review of 228 cases of PBL, 69% were HIV-positive while 39% were HIV-negative. 14 Moreover, six of seven (85.7%) PBL affected patients with orbital presentation described in the literature were HIV-positive. In the present study, two of three patients (66.6%) were HIV-positive. The association with other immunosuppressive states is conflicting. Some studies have reported some form of immunosuppression in HIV-negative patients with PBL, 17 while others found no such immunosuppression. 21 The HIV-negative patient reported by us had no other forms of immunosuppression. Despite the growing literature on PBL, its pathogenesis is still not clear. A large number of molecular and immunohistochemical studies have tried to shed light on this, but no definitive pathogenesis mechanisms have been established. PBL is characterized by immunoblastic morphology and plasma cell phenotype. In other words, plasmablasts are lymphoid cells that morphologically resemble B-cell immunoblasts, but they have acquired a plasma cell immunophenotype. Thus PBL probably develops from postgerminal center, terminally differentiated, active B-cells in transition from immunoblasts to plasma cells. 18 Recent studies have shown MYC gene rearrangements in PBL. 19 [25] [26] [27] Some studies have documented the simultaneous occurrence of Kaposi sarcoma, Castleman disease, and PBL, thus suggesting further associations with PBL. 28 None of the cases of PBL involving the orbit have shown a positive association with HHV-8 to date.
A majority of patients with PBL present with diminution of vision and/or proptosis of the affected eye. Conjunctival chemosis, 9,10 lid swelling, 9 ptosis, 10 and a loss of sensation along the trigeminal nerve 12 are other findings described upon clinical examination. Vision is either reduced or lost in the affected eye. Mild to severe globe motility restriction is a consistent finding on examination. The three patients in the present study showed all of the clinical findings mentioned above in various combinations (Table 2 ). Computed tomography revealed a soft tissue mass that is usually associated with bony destruction. Involvement of the paranasal sinuses, 9, 12, 13 intracranial tissues, 11, 12 nasopharynx, 13 and eyelids 10 in contiguity may be seen. Involvement of the ethmoid sinus, lid, and temporal fossa was seen in the present series. At presentation, involvement of the liver, bone marrow, or lymph nodes is not uncommon given the highly aggressive nature of PBL. 10, 13 Two patients in the present study had an Ann Arbor stage 1 disease, while one patient showed involvement of bone marrow and liver at presentation (Table 2) . Orbital inflammation was the most common differential diagnosis made clinically at presentation. This reflects the challenge posed to the diagnosing physician.
Three categories of PBL have been described in the literature. 13, 29, 30 PBL of the oral mucosa type has a monomorphic population of plasmablasts with minimal or no plasmacytic differentiation. They are found largely in the oral mucosa, but may also occur in other nodal or extranodal sites. PBL with plasmacytic differentiation is composed predominantly of plasmablasts, but exhibits a greater differentiation to mature plasma cells. These cells are round to oval with abundant eosinophilic to amphophilic cytoplasms, an eccentric nucleus, and a prominent nucleolus. Sometimes, a perinuclear Hof may be seen (this is the focal perinuclear clearing seen at the nuclear concavity in plasma cells representing the Golgi zones). 18 The third type of PBL is associated with Castleman disease and is typically nodal or splenic in its location. 31, 32 In the present study, all of the tumors were PBLs with plasmacytic differentiation.
Syndecan-1 (CD138), CD38, VS38c, and multiple myeloma oncogene, MUM1, are consistently expressed by PBL. Staining for CD45 and other B-cell markers, CD20 or CD79a, varies from absent to weak immunoreactivity. Reports on CD10, CD56, and Bcl-6 are conflicting. 5, 10, 12, 25 The Ki-67 index is usually around the 100% mark, thus explaining the highly aggressive nature of PBL. Positive regulatory domain 1 (PRDM1/BL IMP1) protein and activated transcription factor X-box binding protein 1 are proteins that have been recently described to reliably identify PBL, 33 as they are involved in terminal B-cell differentiation. Plasma cell myeloma, Burkitt's lymphoma, DLBCL, anaplastic lymphoma kinase cell lymphoma with plasmacytoid features, and primary effusion lymphoma are other lymphoproliferative lesions that may exhibit a plasmablastic morphology. Detection of paraproteinemia in the blood and/or excess light chains (Bence-Jones proteins) in the urine, lytic bone lesions, and hypercalcemia or anemia favors the diagnosis of plasma cell myeloma over PBL. Negative or weak staining for PAX5 and CD20 coupled with positive staining for PAX5, as well as CD20 coupled with positive staining for PRDM1/BLIMP1 and X-box binding protein 1 help differentiate PBL from DLBCL; as such, a staining pattern is seen in ,5% of DLBCL cases. 34 The strong expression of CD20 and CD79a help to differentiate Burkitt lymphoma from PBL. ALK expression and/or ALK-rearrangement confirm an ALK-positive large cell lymphoma with plasmacytoid features, while HHV-8 immunoreactivity helps to differentiate primary effusion lymphomas. Epstein-Barr virus encoded ribonucleic acid (EBER) in situ hybridization has been positive in a majority of PBL cases involving the orbit, although it can be negative in a minor population of HIV-positive and a large proportion of HIV-negative patients with PBL. 14 We suggest a strong CD138, VS38c immunoreactivity coupled with a negative/weak CD20, CD79a reactivity, and detection of EBER to be confirmative of PBL.
PBL is a fatal disease with a rapid clinical course characterized by relapse, or early death, despite treatment. Of all the cases of PBL with orbital presentation described in the literature, only two survived beyond a period of 10 months past diagnosis. No long term follow-up data are available. Two patients in the present study died within 6 months postdiagnosis, while one is on remission at 3 months postdiagnosis.
No validated guidelines are available for treating PBL. Most clinicians end up treating PBL like other lymphomas. CHOP and CHOP-like regimens have been tried with varying intensities; however, intensifying the CHOP regimen has not been shown to improve overall survival. 20 Rituximab added to the CHOP regimen does not play a role in the treatment of PBL given the CD20-negative nature of these submit your manuscript | www.dovepress.com Autologous stem cell transplantation has been experimented in PBL, but the follow-up data has not encompassed a long enough time-frame to conclude its effectiveness. 37 Responses to bortezomib have been encouraging, but the data available is limited. 38 Overall, the treatment of PBL is quite puzzling; it thus poses a therapeutic challenge to clinicians. The recent advancement has been the identification of a loss of p16 and MDR-1 in PBL.
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Conclusion
Orbital involvement by PBL, although rare, is seen with a higher prevalence in HIV-positive individuals. Recent studies on MYC translocation and the positive identification of EBER have tried to explain the pathogenesis of PBL and its aggressive nature, yet the exact pathogenic mechanisms remain elusive. Morphological and immunohistochemical characteristics overlap with other lymphoproliferative lesions, which pose a diagnostic challenge to the pathologist. Though the treatment of PBL has revolved around CHOP and CHOP-like regimens, no validated treatments are currently available. Features at presentation simulate an inflammatory process, thus making PBL a clinical challenge. Further research is recommended to develop an effective treatment. Lastly, given the aggressive nature of PBL and its propensity to early death despite treatment, early clinical diagnosis may increase the overall survival of such patients.
